In the News | Workplace Wellness | Provant
Nasal Flu Vaccination Update
July 11, 2016 -- Provant
East Greenwich, RI - The Centers for Disease Control and Prevention (CDC) has issued important information about the 2016-2017 influenza season. Although sometimes inaccurately dismissed as a minor illness, influenza causes millions of illnesses and of thousands of deaths each year.
After reviewing preliminary data on the effectiveness of the live attenuated influenza vaccine (LAIV), also known as the “nasal spray” or “flu mist” vaccine, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted that LAIV should not be used during the 2016-2017 flu season.
The ACIP is a panel of immunization experts that advises the CDC. Their vote is based on both CDC and non-CDC data from 2013 through 2016 that indicated that LAIV was less effective than expected at providing protection from seasonal influenza.
Before becoming official CDC policy, the director of the CDC must review and approve these ACIP recommendations. The final 2016-2017 flu vaccination recommendations will be published in late summer or early fall of this year.
The ACIP continues to recommend an annual flu vaccination, with either the inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV), for everyone six months and older.
Back to list
For information regarding Provant's convenient flu vaccination clinics and remote flu vaccination options, please contact us at Connect@provanthealth.com